IMUX vs. CTXR, KNTE, BYSI, RNAC, MCRB, CLSD, ANIX, ORMP, SCTL, and ADAG
Should you be buying Immunic stock or one of its competitors? The main competitors of Immunic include Citius Pharmaceuticals (CTXR), Kinnate Biopharma (KNTE), BeyondSpring (BYSI), Cartesian Therapeutics (RNAC), Seres Therapeutics (MCRB), Clearside Biomedical (CLSD), Anixa Biosciences (ANIX), Oramed Pharmaceuticals (ORMP), Societal CDMO (SCTL), and Adagene (ADAG). These companies are all part of the "pharmaceutical preparations" industry.
Immunic (NASDAQ:IMUX) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, valuation and dividends.
Citius Pharmaceuticals received 113 more outperform votes than Immunic when rated by MarketBeat users. However, 66.91% of users gave Immunic an outperform vote while only 62.05% of users gave Citius Pharmaceuticals an outperform vote.
Immunic has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.
Citius Pharmaceuticals' return on equity of -41.63% beat Immunic's return on equity.
Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.
51.8% of Immunic shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 2.7% of Immunic shares are owned by insiders. Comparatively, 15.0% of Citius Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Immunic had 1 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 2 mentions for Immunic and 1 mentions for Citius Pharmaceuticals. Citius Pharmaceuticals' average media sentiment score of 0.47 beat Immunic's score of 0.31 indicating that Citius Pharmaceuticals is being referred to more favorably in the news media.
Immunic currently has a consensus price target of $7.00, suggesting a potential upside of 438.46%. Citius Pharmaceuticals has a consensus price target of $4.00, suggesting a potential upside of 385.38%. Given Immunic's higher possible upside, equities research analysts plainly believe Immunic is more favorable than Citius Pharmaceuticals.
Summary
Citius Pharmaceuticals beats Immunic on 7 of the 13 factors compared between the two stocks.
Get Immunic News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMUX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools